JP2010539172A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539172A5
JP2010539172A5 JP2010524889A JP2010524889A JP2010539172A5 JP 2010539172 A5 JP2010539172 A5 JP 2010539172A5 JP 2010524889 A JP2010524889 A JP 2010524889A JP 2010524889 A JP2010524889 A JP 2010524889A JP 2010539172 A5 JP2010539172 A5 JP 2010539172A5
Authority
JP
Japan
Prior art keywords
composition
toxoid
clostridium difficile
sodium
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524889A
Other languages
English (en)
Japanese (ja)
Other versions
JP5503543B2 (ja
JP2010539172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/010767 external-priority patent/WO2009035707A1/en
Publication of JP2010539172A publication Critical patent/JP2010539172A/ja
Publication of JP2010539172A5 publication Critical patent/JP2010539172A5/ja
Application granted granted Critical
Publication of JP5503543B2 publication Critical patent/JP5503543B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524889A 2007-09-14 2008-09-15 クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 Active JP5503543B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97249607P 2007-09-14 2007-09-14
US60/972,496 2007-09-14
PCT/US2008/010767 WO2009035707A1 (en) 2007-09-14 2008-09-15 Pharmaceutical compositions containing clostridium difficile toxoids a and b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013241821A Division JP6258674B2 (ja) 2007-09-14 2013-11-22 クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物

Publications (3)

Publication Number Publication Date
JP2010539172A JP2010539172A (ja) 2010-12-16
JP2010539172A5 true JP2010539172A5 (https=) 2011-04-21
JP5503543B2 JP5503543B2 (ja) 2014-05-28

Family

ID=40452372

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010524889A Active JP5503543B2 (ja) 2007-09-14 2008-09-15 クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
JP2013241821A Active JP6258674B2 (ja) 2007-09-14 2013-11-22 クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
JP2016212540A Pending JP2017052773A (ja) 2007-09-14 2016-10-31 クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013241821A Active JP6258674B2 (ja) 2007-09-14 2013-11-22 クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
JP2016212540A Pending JP2017052773A (ja) 2007-09-14 2016-10-31 クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物

Country Status (21)

Country Link
US (3) US9320790B2 (https=)
EP (3) EP3124044B8 (https=)
JP (3) JP5503543B2 (https=)
KR (2) KR20160005378A (https=)
CN (2) CN106039299A (https=)
AU (1) AU2008299885C1 (https=)
BR (1) BRPI0816790A8 (https=)
CA (1) CA2699435A1 (https=)
CY (1) CY1119979T1 (https=)
DK (1) DK2198007T3 (https=)
ES (2) ES2657485T3 (https=)
HR (1) HRP20180054T1 (https=)
HU (1) HUE037932T2 (https=)
IL (1) IL204366A (https=)
MX (1) MX2010002815A (https=)
NO (1) NO2198007T3 (https=)
PL (1) PL2198007T3 (https=)
PT (1) PT2198007T (https=)
RU (1) RU2550271C2 (https=)
SI (1) SI2198007T1 (https=)
WO (1) WO2009035707A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
EP2928489B1 (en) 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
JP6426695B2 (ja) 2013-03-14 2018-11-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 弱毒生アルファウイルス製剤のための組成物および方法
EP2970400A1 (en) * 2013-03-15 2016-01-20 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
KR20150133770A (ko) 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
JP6691477B2 (ja) * 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
BR112015031541A2 (pt) 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
US9930893B2 (en) * 2014-02-10 2018-04-03 The Johns Hopkins University Inhibitors of DXP synthase and methods of use thereof
PT3215530T (pt) 2014-11-07 2019-11-21 Sesen Bio Inc Anticorpos de il-6 melhorados
BR112017024443A2 (pt) 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
CN112512480B (zh) * 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
IL320955A (en) * 2022-12-13 2025-07-01 Pfizer Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
PL170591B1 (pl) 1991-10-16 1997-01-31 Schering Corp Sposób wytwarzania kompozycji farmaceutycznej zawierajacej lipofilowy antybiotyk oligosacharydowy PL PL PL PL PL PL
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
CN1195993A (zh) * 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
PT892054E (pt) * 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
EP2305293A3 (en) * 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
JP2000117967A (ja) * 1998-10-16 2000-04-25 Fuji Photo Film Co Ltd インクジェット記録方法
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US6599715B1 (en) * 1999-05-12 2003-07-29 The Regents Of The University Of California Real time viability detection of bacterial spores
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
AU2003211990A1 (en) 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
WO2003088946A1 (en) * 2002-04-19 2003-10-30 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
AU2005295708A1 (en) 2004-10-13 2006-04-27 Relypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
FR2881139A1 (fr) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech Composition pour la lyophilisation de proteines
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
BRPI0613001B8 (pt) 2005-10-06 2021-05-25 Allergan Inc composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína
WO2007044809A2 (en) * 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
CL2007003209A1 (es) 2006-11-07 2008-05-09 Acambis Inc Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
SG171934A1 (en) 2008-12-03 2011-07-28 Boehringer Ingelheim Vetmed Process for production of vaccines

Similar Documents

Publication Publication Date Title
JP2010539172A5 (https=)
RU2010114730A (ru) Фармацевтические композиции, содержащие анатоксины а и в clostridium difficile
US12097291B2 (en) Thermostable vaccine compositions and methods of preparing same
EP2709657B1 (en) Thermostable vaccine compositions and methods of preparing same
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
Ohtake et al. Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines
JP2014139229A5 (https=)
CA2680193C (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP2011514337A5 (https=)
JP2012531442A5 (https=)
KR20130064741A (ko) 비강내 전달을 위한 방법 및 조성물
JP2015531377A5 (https=)
CN104367558A (zh) 一种奥司他韦冻干口崩片及其制备方法
CN106794145A (zh) 热稳定冻干轮状病毒疫苗制剂及其制备方法
RU2014151424A (ru) Термостабильные составы вакцины
US11224571B2 (en) Oral dispersible vaccine comprising virosomes
BE1024685B1 (fr) Compositions
JP2018514564A5 (https=)
TW201625296A (zh) 發泡性降低之疫苗組合物
US10973900B2 (en) Dried composition
US20230060631A1 (en) Dry liposome adjuvant-containing vaccines and related methods thereof
US9895321B2 (en) Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration
JPWO2023120535A5 (https=)
US20140356396A1 (en) Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures
TH2001003124A (th) สูตรผสมขององค์ประกอบวัคซีนไวรัสเดงกี